Success Metrics

Clinical Success Rate

83.3%

Based on 5 completed trials

Completion Rate

83%(5/6)

Active Trials

1(14%)

Results Posted

40%(2 trials)

Terminated

1(14%)

Phase Distribution

Ph phase_2

14%

Ph early_phase_1

14%

Ph phase_4

29%

Ph not_applicable

14%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution5 total trials

Early Phase 1First-in-human

1(20.0%)

Phase 2Efficacy & side effects

1(20.0%)

Phase 4Post-market surveillance

2(40.0%)

N/ANon-phased studies

1(20.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(5)

Terminated(1)

Detailed Status

Completed5

Terminated1

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

83.3%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (20.0%)

Phase 21 (20.0%)

Phase 42 (40.0%)

N/A1 (20.0%)

Trials by Status

terminated114%

active_not_recruiting114%

completed571%

Recent Activity

1 active trials

Showing 5 of 7

active_not_recruitingphase_2

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

NCT06519357

completedphase_4

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

NCT03360682

terminatedearly_phase_1

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

NCT06056596

completed

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

NCT04002323

completedphase_4

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

NCT04549467

View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials

NCT06519357Phase 2

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Active Not Recruiting

NCT03360682Phase 4

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Completed

NCT06056596Early Phase 1

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Terminated

NCT04002323

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

Completed

NCT04549467Phase 4

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

Completed

NCT04638686

REal-Life Cohort With DOlutegravir + LAmivudina